Cell-Del®氯膦酸盐脂质体

Cell-Del® 氯膦酸盐脂质体（Cell-Del®Clodronate Liposomes）可高效实现体内单核巨噬细胞清除/耗竭。本产品将氯膦酸盐分子包裹于多层囊泡脂质体（MLV）中，活性优异、理化性质稳定且使用便捷。产品采用超高氯膦酸盐 / 脂质配比制备，已完全去除游离氯膦酸盐，脂质体对氯膦酸盐的包封率可达 90% 以上。该脂质体在冰箱中长期存放仍能保持均一混悬状态，产品无黏稠性，注射操作简便，且经无菌工艺生产，保质期更长。

脂质体(Liposomes)是一种人工膜，由磷脂和胆固醇构成。一般直径在25nm-1um之间。细胞体外(invitro)吞噬实验显示，随着脂质体(Liposome)的直径从100nm到1um，细胞吞噬的脂质体(Liposomes)随之增多，直至高达2um；动物体内(invivo)实验显示，随着直径增大，体内吞噬的脂质体(Liposomes)更多。脂质体(Liposomes)和巨噬细胞（Macrophages）间有最小的间隙，辅以改变脂质体(Liposomes)表面的电荷，尤其是负电荷，能更好促进巨噬细胞对脂质体的吞噬。采用多室的脂质体结构，让包裹更多的药物，从而到达效应的阈浓度。

本品支持多种给药途径，包括静脉注射、腹腔注射、皮下注射、鼻内给药、气管内给药等。对体重 20~25 g 的实验动物，单次静脉注射 0.2 mL，24 小时后即可实现肝脏F4/80和CD11b双阳巨噬细胞90%以上；脾脏红髓巨噬细胞 80%~90% 的清除效果。为保证稳定的巨噬细胞清除效率，建议该体重动物的初始给药剂量为 0.15~0.2 mL（静脉 / 腹腔注射均可）；针对特定实验场景和实验目的，建议酌情优化使用剂量。

外观：乳白色混悬液体

脂质组分：磷脂酰胆碱、胆固醇

平均粒径：0.5~3.5 微米

包封药物：二水合氯膦酸钠（CAS 号：22560-50-5），浓度 5 mg/mL

缓冲体系：磷酸盐缓冲液

pH 值：7.0~7.5

保质期：未开启瓶体，2~8 ℃条件下可保质 6 个月

储存条件：避光、4 ℃保存，严禁冷冻

运输方式：采用保温包装 + 蓝冰运输

注意事项

• 产品禁止冻存，避免低于0 ℃。

• 产品静置于冰箱中会出现分层现象（瓶底产生沉淀，上层为澄清液）。

• 使用前请轻柔摇晃，直至体系混合均匀，操作过程中避免产生气泡。

• 产品禁止分装。

• 产品避免接触破环脂质体结构的有机试剂和离子去垢剂。

0. Xia Y, Xie Y, Yu Z, Xiao H, Jiang G, Zhou X, Yang Y, Li X, Zhao M, Li L, Zheng M, Han S, Zong Z, Meng X, Deng H, Ye H, Fa Y, Wu H, Oldfield E, Hu X, Liu W, Shi Y, Zhang Y. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell. 2018 Nov 1;175(4):1059-1073.e21. doi: 10.1016/j.cell.2018.08.070. Epub 2018 Sep 27. PMID: 30270039.  PubMed  (2018年，产品首次被Cell引用)

1. van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res. 1984;238(2):355-8. doi: 10.1007/BF00217308. PMID: 6239690.  PubMed 

2. van Rooijen N, van Nieuwmegen R, Kamperdijk EW. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. Ultrastructural aspects of elimination of marginal zone macrophages. Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;49(4):375-83. doi: 10.1007/BF02912114. PMID: 2867636. PubMed 

3. Claassen E, Kors N, van Rooijen N. Immunomodulation with liposomes: the immune response elicited by liposomes with entrapped dichloromethylene-diphosphonate and surface-associated antigen or hapten. Immunology. 1987 Apr;60(4):509-15. PMID: 2953668; PMCID: PMC1453280. PubMed 

4. van Rooijen N, Kors N, ter Hart H, Claassen E. In vitro and in vivo elimination of macrophage tumor cells using liposome-encapsulated dichloromethylene diphosphonate. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;54(4):241-5. doi: 10.1007/BF02899217. PMID: 2895535. PubMed 

5. van Rooijen N, Kors N, Kraal G. Characterization of cell populations, reappearing in the mouse spleen after elimination by liposome encapsulated dichloromethylene diphosphonate: reappearance of marginal zone lymphocytes is independent of marginal zone macrophages. Adv Exp Med Biol. 1988;237:889-93. doi: 10.1007/978-1-4684-5535-9_133. PMID: 2978212. PubMed 

6. van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol. 1989 Feb;45(2):97-104. doi: 10.1002/jlb.45.2.97. PMID: 2521666. PubMed 

7. Su D, Van Rooijen N. The role of macrophages in the immunoadjuvant action of liposomes: effects of elimination of splenic macrophages on the immune response against intravenously injected liposome-associated albumin antigen. Immunology. 1989 Mar;66(3):466-70. PMID: 2703258; PMCID: PMC1385238.  PubMed 

8. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med. 1989 Aug 1;170(2):499-509. doi: 10.1084/jem.170.2.499. PMID: 2526847; PMCID: PMC2189410. PubMed